Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

For Consumers

Tentative approval of lamivudine tablets

FDA granted tentative approval on March 19, 2007 for lamivudine tablets (150 mg), manufactured by Matrix Laboratories, Inc., of Hyderabad, India,  under expedited review provisions developed for the President's Emergency Plan for AIDS Relief (PEPFAR).  Final approval cannot be granted because the reference drug product, Epivir® Tablets, a product of GlaxoSmithKline, is currently subject to patent protection.

Lamivudine is indicated for use in combination with other antiretroviral agents for the treatment of HIV infection.

FDA's tentative approval of this product means that although existing patents and/or exclusivity prevent marketing of this product in the United States, the product has been shown to meet all of FDA's safety, efficacy, and manufacturing quality standards required for marketing in the U.S., and thus qualifies for consideration for purchase under the PEPFAR program for use in PEPFAR listed countries.

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

Page Last Updated: 08/06/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.